Pre–CAR-T B-cell–directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis
Year: 2026
Type: article
Study design: Observational Study
Abstract: CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) is standard-of-care second-line treatment for relapsed or refractory large B-cell lymphoma (LBCL) [ 1 , 2 , 3 ]. Bispecific antibodies (BSA) and polatuzumab vedotin (pola) are increasingly used prior to CAR-T, but the impact of such exposure, particularly before leukapheresis, when therapies may affect T-cell collection and fitness, remains unclear [ 4 , 5 , 6 , 7 ]. We identified 1158 patients from 38 centers undergoing licensed CD19-directed CAR-T therapy (axicabtagene ciloleucel [axi-cel] or tisagenlecleucel [tisa-cel]) between January 2018 and July 2023 from the European Society for Blood and Marrow Transplantation (EBMT) registry (Table S1 , Fig. S1 ). Pre–CAR-T B-cell–directed immunotherapy (BCDI) was defined as exposure to bispecific antibodies, polatuzumab-based regimens, or other B-cell–directed agents excluding rituximab. Overall survival (OS) was the primary endpoint and outcomes were analyzed using multivariable Cox regression models adjusted for clinically relevant covariates.
Source: Bone Marrow Transplantation
Authors: Jan Christian Schroeder, Christophe Peczynski, Philipp Berning, Eva Michel, Fizza Imran, Lucas Mix, Andreas Riedel, Robin Sanderson, Urban Novak, Ron Ram, Maria-Luisa Schubert, Maxime Delforge, David Beauvais, Daniela Taurino, Robin Noel, Lucia Lopez Corral, Almudena Cabero, Ralph Wäsch, Malte von Bonin, Peter Vandenberghe, Olaf Penack, Björn Chapuy, Avichai Shimoni, Barbara Dreta, Ulf Schnetzke, Eugenio Galli, Tobias Holderried, Claudia Lengerke, Norbert Schmitz, Wolfgang Andreas Bethge, On behalf of the GoCART Coalition
Institutions: Universitätsklinikum Tübingen, University of Tübingen, European Society for Blood and Marrow Transplantation, University of Münster, University Hospital Münster, King's College Hospital, University of Bern, University Hospital of Bern, Tel Aviv University, Tel Aviv Sourasky Medical Center, University Hospital Heidelberg, Centre Hospitalier Universitaire de Lille, IRCCS Humanitas Research Hospital, Complejo Hospitalario de Salamanca, University Medical Center Freiburg, University Hospital Carl Gustav Carus, Universitair Ziekenhuis Leuven, KU Leuven, Charité - Universitätsmedizin Berlin, Sheba Medical Center, University Hospital Centre Zagreb, Jena University Hospital, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, Medical University of Graz, University Hospital Bonn
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,990
OpenAlex ID: W7204891268